Shionogi Looks Beyond Crestor to HIV Platform
This article was originally published in The Pink Sheet Daily
The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.
You may also be interested in...
Daiichi Sankyo, Shionogi Profits Increase; Dainippon Sumitomo Expands In China - Japanese Pharma Earnings Roundup (Part 2 Of 2)
Major Japanese pharma face many of the same problems as major Western pharma, including patent cliffs and growth slowdown in traditional markets. Japanese pharma, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News. Part one of this roundup looked at the approaches Astellas and Eisai are taking to deal with major patent losses (PharmAsia News, May 25, 2010).
Osaka-based Shionogi's board of directors agreed to transfer wholly owned Bushu Pharmaceuticals to private investment fund TMC BUYOUT1, a subsidiary of Tokio Marine Capital beginning March 31. Bushu is the second-largest pharmaceutical contract manufacturer in Japan
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class